
Novo Nordisk (NVO) shares crashed on Tuesday after the Danish drugmaker issued a sobering outlook for 2026 that caught Wall Street flat-footed.
According to the pharma giant, its top- and bottom-line growth will decelerate this year as its “Most Favored Nations” agreement with the U.S. lowers weight-loss drug prices in its largest market.